arrow_back Back to App

Improved Drug Patent Coordination: Agency Collaboration

This act aims to enhance cooperation between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) regarding patents for human drugs and biological products. This will lead to more consistent and efficient drug approval and patenting processes, potentially accelerating access to new therapies and providing greater legal certainty for pharmaceutical companies.
Key points
Establishment of an Interagency Task Force on Patents to facilitate information sharing between USPTO and FDA.
Improved access for patent examiners to FDA data on drugs, aiding in more accurate patent application assessments.
Implementation of confidentiality protocols to safeguard sensitive information from pharmaceutical companies.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_1717
Sponsor: Rep. Neguse, Joe [D-CO-2]
Process start date: 2023-03-22
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Interagency Patent Coordination and Improvement Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_1717.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-22.

What are the main provisions?

Key points include:

  • Establishment of an Interagency Task Force on Patents to facilitate information sharing between USPTO and FDA.
  • Improved access for patent examiners to FDA data on drugs, aiding in more accurate patent application assessments.
  • Implementation of confidentiality protocols to safeguard sensitive information from pharmaceutical companies.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Neguse, Joe [D-CO-2].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on the Judiciary.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health Courts and Law Economy